Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab for eosinophilic COPD with frequent exacerbations
MOH_2019-10-24_007455Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Mepolizumab add-on with Placebo add-on (2 arms). Primary endpoint: Rate of moderate and severe COPD exacerbations. Started Jun 2019; status: active, not recruiting.
02
Drugs
mepolizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on MOH_2019-10-24_007455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-10-24_007455.